Cochrane · systematic review · CD012204
Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus
Hemmingsen, B, Sonne, DP, Metzendorf, MI, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Metabolic and Endocrine DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
11
No studies
3
Included studies
NR
No studies 3 · 21.4%Ungraded 0 · 0%Very low 10 · 71.4%Low 1 · 7.1%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
DPP‐4 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus
Population: people at risk for development of T2DM
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality | no estimate extracted | 1 study · 179 participants | Very low Downgraded: imprecision, indirectness, publication bias |
Incidence of T2DM Definition: WHO criteria | no estimate extracted | 1 study · 179 participants | Very low Downgraded: imprecision, indirectness, publication bias |
Serious adverse events | no estimate extracted | 1 study · 179 participants | Very low Downgraded: imprecision, indirectness, publication bias |
Cardiovascular mortality | no estimate extracted | 1 study · 179 participants | Very low Downgraded: imprecision, indirectness, publication bias |
(1) Non‐fatal myocardial infarction (2) Non‐fatal stroke (3) Congestive heart failure | no estimate extracted | 1 study · 2 participants | Very low Downgraded: imprecision, indirectness, publication bias |
Health‐related quality of life | no estimate extracted | NR | No studies |
Socioeconomic effects | no estimate extracted | NR | No studies |
GLP‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus
Population: people at risk for development of T2DM
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality | no estimate extracted | 2 studies · 2281 participants | Very low Downgraded: risk of bias, imprecision, indirectness, publication bias |
Incidence of T2DM Definition/description: 1 trial established the diagnosis of T2DM defined as HbA1c ≥ 6.5%, or fasting plasma glucose ≥ 7.0 mmol/L, or 2‐hour plasma glucose post‐challenge (oral glucose tolerance test) ≥ 11.1 mmol/L (SCALE). Other... | no estimate extracted | 2 studies · 2243 participants | Very low Downgraded: risk of bias, imprecision, indirectness, publication bias |
Serious adverse events | no estimate extracted | 2 studies · 2312 participants | Low Downgraded: risk of bias, imprecision, publication bias |
Cardiovascular mortality | no estimate extracted | 2 studies · 2281 participants | Very low Downgraded: risk of bias, imprecision, indirectness, publication bias |
(1) Non‐fatal myocardial infarction (2) Non‐fatal stroke (3) Congestive heart failure | no estimate extracted | 1 study · 2279 participants | Very low Downgraded: risk of bias, imprecision, indirectness, publication bias |
Health‐related quality of life SF‐36 scale: total score 0‐100, 8 subscales. Higher values mean better health‐related quality of life. | no estimate extracted | 1 study · 1791 participants | Very low Downgraded: risk of bias, imprecision, indirectness, publication bias |
Socioeconomic effects | no estimate extracted | NR | No studies |